Raynaud's phenomenon in mixed connective tissue disease

Research output: Contribution to journalArticle

Abstract

Raynaud's phenomenon is present almost uniformly in MCTD. Patients who present with Raynaud's phenomenon and a high anti-U1-RNP antibody titer should be watched closely for features of MCTD. In particular, nailfold capillary findings are helpful to distinguish these patients from those who have primary Raynaud's phenomenon. Cardiopulmonary complications, including pulmonary hypertension, are a risk among patients who present with Raynaud's phenomenon and anti-U1-RNP antibodies. Although Raynaud's phenomenon tends to be less severe in patients who have MCTD compared with those who have scleroderma, its pathogenesis seems to be similar. Specific recommendations for therapy for Raynaud's phenomenon in MCTD are not yet established, but it makes sense to follow the management that is used in patients who have scleroderma.

Original languageEnglish (US)
Pages (from-to)465-481
Number of pages17
JournalRheumatic Disease Clinics of North America
Volume31
Issue number3
DOIs
StatePublished - Aug 2005

Fingerprint

Mixed Connective Tissue Disease
Raynaud Disease
Antibodies
Pulmonary Hypertension

ASJC Scopus subject areas

  • Rheumatology

Cite this

Raynaud's phenomenon in mixed connective tissue disease. / Grader Beck, Thomas; Wigley, Fredrick.

In: Rheumatic Disease Clinics of North America, Vol. 31, No. 3, 08.2005, p. 465-481.

Research output: Contribution to journalArticle

@article{02593d03fae34d228e55c458b37ededd,
title = "Raynaud's phenomenon in mixed connective tissue disease",
abstract = "Raynaud's phenomenon is present almost uniformly in MCTD. Patients who present with Raynaud's phenomenon and a high anti-U1-RNP antibody titer should be watched closely for features of MCTD. In particular, nailfold capillary findings are helpful to distinguish these patients from those who have primary Raynaud's phenomenon. Cardiopulmonary complications, including pulmonary hypertension, are a risk among patients who present with Raynaud's phenomenon and anti-U1-RNP antibodies. Although Raynaud's phenomenon tends to be less severe in patients who have MCTD compared with those who have scleroderma, its pathogenesis seems to be similar. Specific recommendations for therapy for Raynaud's phenomenon in MCTD are not yet established, but it makes sense to follow the management that is used in patients who have scleroderma.",
author = "{Grader Beck}, Thomas and Fredrick Wigley",
year = "2005",
month = "8",
doi = "10.1016/j.rdc.2005.04.006",
language = "English (US)",
volume = "31",
pages = "465--481",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Raynaud's phenomenon in mixed connective tissue disease

AU - Grader Beck, Thomas

AU - Wigley, Fredrick

PY - 2005/8

Y1 - 2005/8

N2 - Raynaud's phenomenon is present almost uniformly in MCTD. Patients who present with Raynaud's phenomenon and a high anti-U1-RNP antibody titer should be watched closely for features of MCTD. In particular, nailfold capillary findings are helpful to distinguish these patients from those who have primary Raynaud's phenomenon. Cardiopulmonary complications, including pulmonary hypertension, are a risk among patients who present with Raynaud's phenomenon and anti-U1-RNP antibodies. Although Raynaud's phenomenon tends to be less severe in patients who have MCTD compared with those who have scleroderma, its pathogenesis seems to be similar. Specific recommendations for therapy for Raynaud's phenomenon in MCTD are not yet established, but it makes sense to follow the management that is used in patients who have scleroderma.

AB - Raynaud's phenomenon is present almost uniformly in MCTD. Patients who present with Raynaud's phenomenon and a high anti-U1-RNP antibody titer should be watched closely for features of MCTD. In particular, nailfold capillary findings are helpful to distinguish these patients from those who have primary Raynaud's phenomenon. Cardiopulmonary complications, including pulmonary hypertension, are a risk among patients who present with Raynaud's phenomenon and anti-U1-RNP antibodies. Although Raynaud's phenomenon tends to be less severe in patients who have MCTD compared with those who have scleroderma, its pathogenesis seems to be similar. Specific recommendations for therapy for Raynaud's phenomenon in MCTD are not yet established, but it makes sense to follow the management that is used in patients who have scleroderma.

UR - http://www.scopus.com/inward/record.url?scp=23444442524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23444442524&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2005.04.006

DO - 10.1016/j.rdc.2005.04.006

M3 - Article

C2 - 16084319

AN - SCOPUS:23444442524

VL - 31

SP - 465

EP - 481

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 3

ER -